

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Domány, et al.

Group Art Unit: Not yet assigned

Serial No.: Not yet assigned

Examiner: Not yet assigned

Filed: January 21, 2004

For: Piperidine Derivatives as NMDA Receptor
Antagonists

Attorney Docket No.: 1000546-0003

Assistant Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


The Applicants and their attorney are aware of the patents, publications or other information that relate to the current application and are cited on the attached PTO Form 1449. In accordance with 37 CFR § 1.97, Applicants hereby submit these forms for the Examiner's consideration.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant understands that the Examiner will make an independent evaluation of the cited publications.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 122144.

Respectfully submitted,

LORD, BISSELL & BROOK LLP


Matthew O. Brady
Registration No. 44,554
Attorney for Applicant

Matthew O. Brady
LORD, BISSELL & BROOK LLP
115 South LaSalle Street
Chicago, IL 60603
312-443-0616

Date: January 21, 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	n/a
Filing Date	January 21, 2004
First Named Inventor	Gyorgy Domány
Art Unit	n/a
Examiner Name	n/a
Attorney Docket Number	1000546-0003

Sheet	1	of	2
-------	---	----	---

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)	MM-DD-YYYY			
	B1	EP 0824098 A1	02-18-1998	F. Hoffman-LaR.		
	B2	EP 0648744 A1	04-19-1995	F. Hoffman-LaR.		
	B3	FR 2672286 A	08-07-1992	Synthelabo S.A		
	B4	WO 97/23216 A1	07-03-1997	Warner-Lambert		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	n/a
		Filing Date	January 21, 2004
		First Named Inventor	Gyorgy Domány
		Art Unit	n/a
		Examiner Name	n/a
Sheet 2 of 2	Attorney Docket Number	1000546-0003	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	B.L. CHENARD, et al., Separation of (alpha) Adrenergic and N-Methyl-D-Aspartate Antagonist Act. in a Series of Ifenprodil Cpd's., J. Med. Chem., 1941, 3085-3090, Vol. 34, No. 10	
	C2	C. DOMINGUEZ, et al., Design and Synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors, Bio Org. Med. Chem. Lett., 1999, 925-930, Vol. 9	
	C3	PCT International Search Report for Int'l Application No. PCT/HU02/00071 (later published as WO 03/010159 A1)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.